Literature DB >> 23110998

Heart failure performance measures: do they have an impact on 30-day readmission rates?

Sula Mazimba1, Nakash Grant, Analkumar Parikh, George Mwandia, Diklar Makola, Christine Chilomo, Cristina Redko, Harvey S Hahn.   

Abstract

Congestive heart failure (CHF) accounts for more health care costs than any other diagnosis. Readmissions contribute to this expenditure. The authors evaluated the relationship between adherence to performance metrics and 30-day readmissions. This was a retrospective study of 6063 patients with CHF between 2001 and 2008. Data were collected for 30-day readmissions and compliance with CHF performance measures at discharge. Rates of readmission for CHF increased from 16.8% in 2002 to 24.8% in 2008. Adherence to performance measures increased concurrently from 95.8% to 99.9%. Except for left ventricular function (LVF) assessment, the 30-day readmission rate was not associated with adherence to performance measures. Readmitted patients had twice the odds of not having their LVF assessed (odds ratio = 2.0; P < .00005; 95% confidence interval = 1.45-2.63). CHF performance measures, except for the LVF assessment, have little relationship to 30-day readmissions. Further studies are needed to identify performance measures that correlate with quality of care.

Entities:  

Keywords:  CHF; core measures; quality; readmissions

Mesh:

Substances:

Year:  2012        PMID: 23110998     DOI: 10.1177/1062860612465066

Source DB:  PubMed          Journal:  Am J Med Qual        ISSN: 1062-8606            Impact factor:   1.852


  2 in total

1.  Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure.

Authors:  Richard H Tran; Ahmed Aldemerdash; Patricia Chang; Carla A Sueta; Brystana Kaufman; Josephine Asafu-Adjei; Orly Vardeny; Eliza Daubert; Khalid A Alburikan; Anna M Kucharska-Newton; Sally C Stearns; Jo E Rodgers
Journal:  Pharmacotherapy       Date:  2018-03-22       Impact factor: 4.705

2.  Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a medicare population.

Authors:  Ramez N Eskander; Jenny Chang; Argyrios Ziogas; Hoda Anton-Culver; Robert E Bristow
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.